Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
Compass Therapeutics announced encouraging Phase 1 trial results of CTX-8371, a novel bispecific antibody targeting PD-1 and PD-L1, demonstrating deep and durable responses in patients with advanced malignancies resistant to prior immune checkpoint inhibitors. The drug showed clinical activity in triple-negative breast cancer, Hodgkin lymphoma, and…